Background: This cohort study aimed to investigate the influence of fibrinogen on progression-free survival and overall survival in unresectable HCC cases treated by PD-1 and lenvatinib.
Methods: A total of 57 unresectable HCC cases who received lenvatinib and PD-1, such as toripalimab, camrelizumab, or sintilimab, in Beijing Ditan Hospital Affiliated to Capital Medical University were enrolled in this study.
Results: Vascular invasion, high FIB (> 2.83g/L), and metastasis were highly correlated with low PFS. There was a significant correlation between a raised risk of death and metastasis and increased FIB (> 2.83g/L).
Conclusion: FIB is associated with outcomes of unresectable HCC cases treated by PD-1 and lenvatinib.
Keywords: FIB, lenvatinib, PD-1, prediction, hepatocellular carcinoma